ArticleAnnals of internal medicine2018
Low Prevalence of Hepatitis B Vaccination Among Patients Receiving Medical Care for HIV Infection in the United States, 2009 to 2012.
Article in Annals of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Burden of vaccine-preventable diseases among at-risk adult populations in the US.Human vaccines & immunotherapeutics · 2022Pooled it
- Vaccine uptake and barriers to vaccination among at-risk adult populations in the US.Human vaccines & immunotherapeutics · 2022Pooled it
- Comparative Efficacy of a High-Dose vs Standard-Dose Hepatitis B Revaccination Schedule Among Patients With HIV: A Randomized Clinical Trial.JAMA network open · 2021Trial
- Older Adults and Vaccination Status: A Cross-Sectional Analysis of the "ECORSINOS" Study.AIDS and behavior · 2026Article
- Hepatic Viral Reservoirs in Concurrent HIV and HBV: From Mechanistic Insight to Integrated Cure Strategies.Infection and drug resistance · 2026Review
- Enhancing Hepatitis B Virus Vaccine Uptake and Immunity Through Long-Acting Antiretroviral Therapy Programmatic Synergy in the US South.Open forum infectious diseases · 2025Article
- Immunological and Clinical Responses to Vaccinations among Adults Living with HIV.Life (Basel, Switzerland) · 2024Review
- Risk of hepatocellular carcinoma in people with HIV in the United States, 2001-2019.Journal of the National Cancer Institute · 2024Article
- Strategies for Hepatitis B Virus Prevention in People Living with HIV.Current HIV/AIDS reports · 2023Review
- Delays in Hepatitis B Immunization Series Completion in People With Human Immunodeficiency Virus.Open forum infectious diseases · 2023Article
- Who Is at Risk for New Hepatitis B Infections Among People With HIV?Open forum infectious diseases · 2023Article
- Chronic hepatitis B and HIV coinfection.Topics in antiviral medicine · 2023Review
- Comparison of hepatitis B and SARS-CoV2 vaccination rates in people who attended Drugs and Addiction Centres.Frontiers in public health · 2023Article
- Sociodemographic, HIV-Related Characteristics, and Health Care Factors as Predictors of Self-Reported Vaccination Coverage in a Nationwide Sample of People Aging with HIV in Germany.International journal of environmental research and public health · 2021Article
- Predictors of vaccination rates in people living with HIV followed at a specialty care clinic.Human vaccines & immunotherapeutics · 2021Article
- Occult hepatitis B virus infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults.PloS one · 2021Article
- Chronic Hepatitis B and HIV Coinfection: A Continuing Challenge in the Era of Antiretroviral Therapy.Current hepatology reports · 2020Article
- Trends in Prevalence of Protective Levels of Hepatitis B Surface Antibody Among Adults Aged 18-49 Years With Risk Factors for Hepatitis B Virus Infection-United States, 2003-2014.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Persons with HIV infection are at increased risk for hepatitis B virus infection. In 2016, the World Health Organization resolved to eliminate hepatitis B as a public health threat by 2030. Objective: To estimate the prevalence of hepatitis B vaccination among U.S. patients receiving medical care for HIV infection ("HIV patients"). Design: Nationally representative cross-sectional survey. Setting: United States. Participants: 18 089 adults receiving HIV medical care who participated in the Medical Monitoring Project during 2009 to 2012. Measurements: Primary outcomes were prevalence of 1) no documentation of hepatitis B vaccination or laboratory evidence of immunity or infection (candidates to initiate vaccination), and 2) initiation of vaccination among candidates, defined as documentation of at least 1 vaccine dose in a 1-year surveillance period during which patients received ongoing HIV medical care. Results: At the beginning of the surveillance period, 44.2% (95% CI, 42.2% to 46.2%) of U.S. HIV patients were candidates to initiate vaccination. By the end of the surveillance period, 9.6% (CI, 8.4% to 10.8%) of candidates were vaccinated, 7.5% (CI, 6.4% to 8.6%) had no documented vaccination but had documented infection or immunity, and 82.9% (CI, 81.1% to 84.7%) remained candidates. Among patients at facilities funded by the Ryan White HIV/AIDS Program (RWHAP), 12.5% (CI, 11.1% to 13.9%) were vaccinated during the surveillance period versus 3.7% (CI, 2.6% to 4.7%) at facilities not funded by RWHAP. At the end of surveillance, 36.7% (CI, 34.4% to 38.9%) of HIV patients were candidates to initiate vaccination. Limitation: The study was not designed to describe vaccine series completion or actual prevalence of immunity. Conclusion: More than one third of U.S. HIV patients had missed opportunities to initiate hepatitis B vaccination. Meeting goals for hepatitis B elimination will require increased vaccination of HIV patients in all practice settings, particularly at facilities not funded by RWHAP. Primary Funding Source: Centers for Disease Control and Prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.